Inamrinone

Summary

Inamrinone (CHEMBL12856) is an approved small-molecule EC 3.1.4.* (phosphoric diester hydrolase) inhibitor (ATC C01CE01) targeting PDE3A and PDE3B; indicated across 1 condition including cardiovascular disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C01CE01
• Targets: 2 (PDE3A, PDE3B)
• Indications: 1 condition
• Chemistry: 187.2 Da · C10H9N3O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL12856
Name	Inamrinone
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3698
ChEBI	CHEBI:2686
ATC	C01CE01
Molecular formula	C10H9N3O
Molecular weight	187.2
InChIKey	RNLQIBCLLYYYFJ-UHFFFAOYSA-N

SMILES: C1=CN=CC=C1C2=CNC(=O)C(=C2)N

IUPAC name: 3-amino-5-pyridin-4-yl-1H-pyridin-2-one

ChEBI definition: A 3,4’-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure.

Pharmacological roles (ChEBI): EC 3.1.4.* (phosphoric diester hydrolase) inhibitor, cardiovascular drug.

Also known as: Amcoral, Amrinona, Amrinone, C01CE01, Cartonic, Cordemcura, Inamrinone, NSC-759805, Vesistol, WIN 40680, WIN-40680, Wincoram

Parent form; salt/anhydrous children: CHEMBL2096642

Patent coverage: 2,680 distinct patent families (9,690 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 9,689 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
PDE3A	phosphodiesterase 3A	Inhibition	4.8	0.1%	Q14432
PDE3B	phosphodiesterase 3B	Inhibition	4.51	0.2%	Q13370

Broader ChEMBL bioactivity targets: 36 (assay-derived). Sample: Microtubule-associated protein tau, Lysine-specific demethylase 4E, Nuclear receptor ROR-gamma, Survival motor neuron protein, Fructose-bisphosphate aldolase, Prelamin-A/C, ATP-dependent DNA helicase Q1, RecQ-like DNA helicase BLM, 4’-phosphopantetheinyl transferase ffp, Ferritin light chain, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], Alpha-2B adrenergic receptor, Thyroid hormone receptor beta, Beta-lactamase, Menin/Histone-lysine N-methyltransferase MLL, Phosphodiesterase 4, Phosphodiesterase 3, Phosphodiesterase; PDE3 & PDE4, cGMP-inhibited 3’,5’-cyclic phosphodiesterase 3A, Alpha-galactosidase A.

Bioactivity

ChEMBL activities: 29 potent at pChembl ≥ 5 of 80 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P02791	6.55	Potency	281.8	nM	CHEMBL_ACT_4491761
LMNA	6.5	Potency	316.2	nM	CHEMBL_ACT_3660379
HTT	6.3	Potency	501.2	nM	CHEMBL_ACT_3749757
KDM4E	5.95	Potency	1122	nM	CHEMBL_ACT_3733314
HSD17B10	5.9	Potency	1259	nM	CHEMBL_ACT_4829782
GLA	5.9	Potency	1259	nM	CHEMBL_ACT_4849183
MAPT	5.85	Potency	1412	nM	CHEMBL_ACT_4061090
A8B2U2	5.75	Potency	1774	nM	CHEMBL_ACT_4611837
MAPT	5.7	Potency	1995	nM	CHEMBL_ACT_4525518
ADRA2B	5.64	AC50	2300	nM	CHEMBL_ACT_25144361
CYP3A4	5.5	Potency	3162	nM	CHEMBL_ACT_5006308
CYP3A4	5.5	Potency	3162	nM	CHEMBL_ACT_5074815
CYP3A4	5.5	AC50	3162	nM	CHEMBL_ACT_6053661
MAPT	5.45	Potency	3548	nM	CHEMBL_ACT_4044933
A8B2U2	5.45	Potency	3540	nM	CHEMBL_ACT_4600411
HIF1A	5.4	Potency	3981	nM	CHEMBL_ACT_4128841
HIF1A	5.4	Potency	3981	nM	CHEMBL_ACT_4520663
A8B2U2	5.4	Potency	3972	nM	CHEMBL_ACT_4608785
MAPT	5.35	Potency	4467	nM	CHEMBL_ACT_4505683
PDE4A	5.32	IC50	4800	nM	CHEMBL_ACT_172836
MAPT	5.3	Potency	5012	nM	CHEMBL_ACT_3971813
CYP2C19	5.3	Potency	5012	nM	CHEMBL_ACT_4015454
CYP2C19	5.3	AC50	5012	nM	CHEMBL_ACT_6056783
Q9F4F7	5.25	Potency	5623	nM	CHEMBL_ACT_4399453
Q9F4F7	5.2	Potency	6310	nM	CHEMBL_ACT_4374675
MEN1	5.2	Potency	6310	nM	CHEMBL_ACT_4592405
MAPT	5.05	Potency	8912	nM	CHEMBL_ACT_3904894
HSD17B10	5	Potency	10000	nM	CHEMBL_ACT_3712667
MAPT	5	Potency	10000	nM	CHEMBL_ACT_3953035

Target pathways

Aggregated over 2 target gene(s): PDE3A, PDE3B.

Top Reactome pathways

2 total, by targets touching each:

Pathway	Targets	Genes
G alpha (s) signalling events	2	PDE3A, PDE3B
PDE3B signalling	1	PDE3B

Dominant GO biological processes

GO term	Targets
G protein-coupled receptor signaling pathway	2
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway	2
negative regulation of cAMP/PKA signal transduction	2
signal transduction	2
oocyte maturation	1
lipid metabolic process	1
response to xenobiotic stimulus	1
regulation of meiotic nuclear division	1
negative regulation of apoptotic process	1
negative regulation of vascular permeability	1
positive regulation of vascular permeability	1
positive regulation of oocyte development	1
regulation of ribonuclease activity	1
cellular response to cGMP	1
cellular response to transforming growth factor beta stimulus	1

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

200 molecules share ≥1 primary target. Top 100 by shared-target count:

Molecule	Source	Status	Shared targets
ANAGRELIDE	ChEMBL + PubChem	Phase 4 (approved)	PDE3A, PDE3B
LOSARTAN	ChEMBL + PubChem	Phase 4 (approved)	PDE3A, PDE3B
SILDENAFIL	ChEMBL + PubChem	Phase 4 (approved)	PDE3A, PDE3B
VARDENAFIL	ChEMBL + PubChem	Phase 4 (approved)	PDE3A, PDE3B
CILOSTAZOL	ChEMBL	Phase 4 (approved)	PDE3A, PDE3B
CRISABOROLE	ChEMBL	Phase 4 (approved)	PDE3A, PDE3B
DIPYRIDAMOLE	ChEMBL	Phase 4 (approved)	PDE3A, PDE3B
ENOXIMONE	ChEMBL	Phase 4 (approved)	PDE3A, PDE3B
IBUDILAST	ChEMBL	Phase 4 (approved)	PDE3A, PDE3B
MILRINONE	ChEMBL	Phase 4 (approved)	PDE3A, PDE3B
LEVOSIMENDAN	ChEMBL	Phase 3	PDE3A, PDE3B
PAPAVERINE	ChEMBL	Phase 3	PDE3A, PDE3B
ADIBENDAN	ChEMBL	Phase 2	PDE3A, PDE3B
BEMARINONE	ChEMBL	Phase 2	PDE3A, PDE3B
BEMORADAN	ChEMBL	Phase 2	PDE3A, PDE3B
CC-115	ChEMBL	Phase 2	PDE3A, PDE3B
CILOSTAMIDE	ChEMBL	Phase 2	PDE3A, PDE3B
ETAZOLATE	ChEMBL	Phase 2	PDE3A, PDE3B
IMAZODAN	ChEMBL	Phase 2	PDE3A, PDE3B
INDOLIDAN	ChEMBL	Phase 2	PDE3A, PDE3B
ISOMAZOLE	ChEMBL	Phase 2	PDE3A, PDE3B
LIXAZINONE	ChEMBL	Phase 2	PDE3A, PDE3B
MEDORINONE	ChEMBL	Phase 2	PDE3A, PDE3B
MERIBENDAN	ChEMBL	Phase 2	PDE3A, PDE3B
ORISMILAST	ChEMBL	Phase 2	PDE3A, PDE3B
OXAGRELATE	ChEMBL	Phase 2	PDE3A, PDE3B
PIMOBENDAN	ChEMBL	Phase 2	PDE3A, PDE3B
PIROXIMONE	ChEMBL	Phase 2	PDE3A, PDE3B
QUAZINONE	ChEMBL	Phase 2	PDE3A, PDE3B
SIMENDAN	ChEMBL	Phase 2	PDE3A, PDE3B
SULMAZOLE	ChEMBL	Phase 2	PDE3A, PDE3B
VESNARINONE	ChEMBL	Phase 2	PDE3A, PDE3B
ZARDAVERINE	ChEMBL	Phase 2	PDE3A, PDE3B
Tadalafil	PubChem	Approved	PDE3A, PDE3B
CLOFARABINE	ChEMBL + PubChem	Phase 4 (approved)	PDE3A
IDELALISIB	ChEMBL + PubChem	Phase 4 (approved)	PDE3A
TAFAMIDIS	ChEMBL + PubChem	Phase 4 (approved)	PDE3A
TAVABOROLE	ChEMBL + PubChem	Phase 4 (approved)	PDE3A
ACARBOSE	ChEMBL	Phase 4 (approved)	PDE3A
ADENOSINE	ChEMBL	Phase 4 (approved)	PDE3A
ALECTINIB	ChEMBL	Phase 4 (approved)	PDE3A
ALENDRONIC ACID	ChEMBL	Phase 4 (approved)	PDE3A
AMINOGLUTETHIMIDE	ChEMBL	Phase 4 (approved)	PDE3A
AMLEXANOX	ChEMBL	Phase 4 (approved)	PDE3A
ANTAZOLINE	ChEMBL	Phase 4 (approved)	PDE3A
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	PDE3A
BENAZEPRIL	ChEMBL	Phase 4 (approved)	PDE3A
BENZBROMARONE	ChEMBL	Phase 4 (approved)	PDE3A
BITHIONOL	ChEMBL	Phase 4 (approved)	PDE3A
CABOZANTINIB	ChEMBL	Phase 4 (approved)	PDE3A
CALCITRIOL	ChEMBL	Phase 4 (approved)	PDE3A
CANDESARTAN CILEXETIL	ChEMBL	Phase 4 (approved)	PDE3A
CANNABIDIOL	ChEMBL	Phase 4 (approved)	PDE3A
CEFOPERAZONE	ChEMBL	Phase 4 (approved)	PDE3A
CHLORHEXIDINE	ChEMBL	Phase 4 (approved)	PDE3A
CHLOROQUINE	ChEMBL	Phase 4 (approved)	PDE3A
CHOLIC ACID	ChEMBL	Phase 4 (approved)	PDE3A
CINNARIZINE	ChEMBL	Phase 4 (approved)	PDE3A
CLADRIBINE	ChEMBL	Phase 4 (approved)	PDE3A
CODEINE	ChEMBL	Phase 4 (approved)	PDE3A
DEOXYCHOLIC ACID	ChEMBL	Phase 4 (approved)	PDE3A
DEQUALINIUM	ChEMBL	Phase 4 (approved)	PDE3A
DISOPYRAMIDE	ChEMBL	Phase 4 (approved)	PDE3A
DUVELISIB	ChEMBL	Phase 4 (approved)	PDE3A
EFAVIRENZ	ChEMBL	Phase 4 (approved)	PDE3A
ENCORAFENIB	ChEMBL	Phase 4 (approved)	PDE3A
ESTRADIOL CYPIONATE	ChEMBL	Phase 4 (approved)	PDE3A
ESTRADIOL VALERATE	ChEMBL	Phase 4 (approved)	PDE3A
ETHINYL ESTRADIOL	ChEMBL	Phase 4 (approved)	PDE3A
FEXOFENADINE	ChEMBL	Phase 4 (approved)	PDE3A
GEMCITABINE	ChEMBL	Phase 4 (approved)	PDE3A
GRISEOFULVIN	ChEMBL	Phase 4 (approved)	PDE3A
HEXACHLOROPHENE	ChEMBL	Phase 4 (approved)	PDE3A
HYDROXOCOBALAMIN	ChEMBL	Phase 4 (approved)	PDE3A
HYDROXYPROGESTERONE CAPROATE	ChEMBL	Phase 4 (approved)	PDE3A
IBANDRONIC ACID	ChEMBL	Phase 4 (approved)	PDE3A
IDEBENONE	ChEMBL	Phase 4 (approved)	PDE3A
IFOSFAMIDE	ChEMBL	Phase 4 (approved)	PDE3A
ILOPERIDONE	ChEMBL	Phase 4 (approved)	PDE3A
INDOCYANINE GREEN ACID FORM	ChEMBL	Phase 4 (approved)	PDE3A
IRBESARTAN	ChEMBL	Phase 4 (approved)	PDE3A
ISOPROTERENOL	ChEMBL	Phase 4 (approved)	PDE3A
ISRADIPINE	ChEMBL	Phase 4 (approved)	PDE3A
LAMIVUDINE	ChEMBL	Phase 4 (approved)	PDE3A
LAMOTRIGINE	ChEMBL	Phase 4 (approved)	PDE3A
MASOPROCOL	ChEMBL	Phase 4 (approved)	PDE3A
MECLIZINE	ChEMBL	Phase 4 (approved)	PDE3A
METHICILLIN	ChEMBL	Phase 4 (approved)	PDE3A
MIZOLASTINE	ChEMBL	Phase 4 (approved)	PDE3A
MOEXIPRIL	ChEMBL	Phase 4 (approved)	PDE3A
MOFEZOLAC	ChEMBL	Phase 4 (approved)	PDE3A
MONTELUKAST	ChEMBL	Phase 4 (approved)	PDE3A
MYCOPHENOLATE MOFETIL	ChEMBL	Phase 4 (approved)	PDE3A
NEVIRAPINE	ChEMBL	Phase 4 (approved)	PDE3A
NISOLDIPINE	ChEMBL	Phase 4 (approved)	PDE3A
NITROFURAZONE	ChEMBL	Phase 4 (approved)	PDE3A
NORETHYNODREL	ChEMBL	Phase 4 (approved)	PDE3A
OLAPARIB	ChEMBL	Phase 4 (approved)	PDE3A
OLMESARTAN MEDOXOMIL	ChEMBL	Phase 4 (approved)	PDE3A
PAMIDRONIC ACID	ChEMBL	Phase 4 (approved)	PDE3A